JNJ Johnson & Johnson

160.3
-0.35  -0%
Previous Close 160.65
Open 160.3
52 Week Low 109.16
52 Week High 161.95
Market Cap $421,996,590,322
Shares 2,632,542,672
Float 2,631,008,571
Enterprise Value $428,973,590,321
Volume 7,618,310
Av. Daily Volume 7,812,409
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
JNJ-78436735 (Ad26.COV2-S)
COVID-19 vaccine
Phase 3
Phase 3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
DARZALEX (Daratumumab) using ENHANZE
Amyloidosis
Approved
Approved
FDA approval announced January 15, 2021.
Guselkumab
Ulcerative colitis
Phase 2
Phase 2
Phase 2a initiation announced January 17, 2019.
Bermekimab
Systemic Sclerosis
Phase 2
Phase 2
Phase 2 commencement of enrolment announced October 2, 2019.
Daratumumab in combination with pomalidomide and dexamethasone
Multiple myeloma
sNDA Filing
sNDA Filing
sBLA filing announced November 12, 2020.
Amivantamab
Non-small cell lung cancer (NSCLC)
BLA Filing
BLA Filing
BLA filing announced December 3, 2020.
Paliperidone
Schizophrenia
sNDA Filing
sNDA Filing
sNDA filing announced November 2, 2020.
Nipocalimab (M281)
generalized myasthenia gravis (gMG)
Phase 2
Phase 2
Phase 2 trial met primary endpoint - June 15, 2020. Phase 3 trial to be initiated 1Q 2021.
Generic Copaxone
Multiple sclerosis
Approved
Approved
Filed 2007. Approved April 16 2015.
Erdafitinib
Urothelial cancer
Approved
Approved
FDA Approval announced April 12, 2019.
Bermekimab
Atopic Dermatitis (AD)
Phase 2
Phase 2
Phase 2 commencement of enrolment announced November 12, 2019.
Bermekimab
Hidradenitis Suppurativa (HS)
Phase 2
Phase 2
Phase 2 commencement of enrolment announced October 23, 2019.
Darzalex (daratumumab) and Kyprolis (carfilzomib)
Multiple Myeloma
Approved
Approved
FDA approval announced August 20, 2020.
Esketamine
Major depressive disorder (MDD)
Approved
Approved
FDA approval announced August 3, 2020.
Guselkumab
Psoriatic Arthritis
Approved
Approved
FDA Approval announced July 14, 2020.
Guselkumab (NOVA)
Hidradenitis Suppurativa
Phase 2
Phase 2
Phase 2 trial initiation announced November 19, 2018.
DARZALEX (Daratumumab) using ENHANZE
Multiple myeloma
Approved
Approved
FDA Approval announced May 1, 2020.
IMBRUVICA (ibrutinib) and rituximab
Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Approved
Approved
FDA Approval announced April 21, 2020.
Ponesimod
Relapsing multiple sclerosis
NDA Filing
NDA Filing
NDA filing announced March 18, 2020.
Dolutegravir + rilpivirine
HIV
CRL
CRL
Complete Response Letter issued December 21, 2019.
STELARA (USTEKINUMAB)
Ulcerative colitis
Approved
Approved
FDA Approval announced October 21, 2019.
XARELTO (rivaroxaban)
Reduce the Risk of Recurrent Venous Thromboembolism (VTE)
Approved
Approved
FDA approval announced October 14, 2019.
STELARA (USTEKINUMAB)
Plaque psoriasis - pediatric
sNDA Filing
sNDA Filing
sBLA filing announced October 7, 2019.
INVOKANA - CREDENCE
Diabetic Kidney Disease
Approved
Approved
FDA Approval announced September 30, 2019.
Daratumumab + VTD
Multiple myeloma - candidates for autologous stem cell transplant (ASCT)
Approved
Approved
FDA Approval announced September 26, 2019.
Apalutamide
Metastatic castration-sensitive prostate cancer (mCSPC).
Approved
Approved
FDA Approval announced September 18, 2019.
DARZALEX (Daratumumab) + pomalidomide and dexamethasone
Relapsed or refractory multiple myeloma
Approved
Approved
Approval announced June 16, 2017 - note: submitted by Janssen Biotech, Inc.
Daratumumab - MAIA
Newly Diagnosed Multiple Myeloma (NDMM)
Approved
Approved
FDA Approval announced June 28, 2019.
Guselkumab vs Cosentyx - ECLIPSE
Psoriasis
Phase 3
Phase 3
Phase 3 primary endpoint met - December 12, 2018.
Guselkumab (GALAXI 1)
Crohn's disease
Phase 2/3
Phase 2/3
Phase 2/3 trial initiation announced July 11, 2018.
Esketamine
Treatment resistant depression
Approved
Approved
FDA approval announced March 5, 2019.
Guselkumab
Plaque psoriasis
Approved
Approved
Approval announced February 27, 2019.
Apalutamide
Non-metastatic castration-resistant prostate cancer (CRPC)
Approved
Approved
Approval announced February 14, 2018.
INVOKANA CANVAS
Type 2 diabetes
Approved
Approved
FDA Approval announced October 30, 2018.
IMBRUVICA (ibrutinib)
Waldenström’s Macroglobulinemia
Approved
Approved
FDA approval announced August 27, 2018.
D/C/F/TAF
HIV
Approved
Approved
FDA Approval announced July 17, 2018.
IMBRUVICA (ibrutinib)
Diffuse large B-cell lymphoma (DLBCL)
Phase 3
Phase 3
Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
Atabecestat
Alzheimer’s disease
Phase 2
Phase 2
Announced May 18, 2018 that dosing will be stopped.
DARZALEX (Daratumumab) - ALCYONE
Frontline multiple myeloma (non-transplant)
Approved
Approved
Approval announced May 7, 2018.
ZYTIGA (abiraterone acetate) - LATITUDE
metastatic hormone-naïve prostate cancer (mHNPC)
Approved
Approved
sNDA approval announced February 8, 2018.
Sirukumab
Rheumatoid arthritis
CRL
CRL
CRL issued September 22, 2017. Advisory Committee Meeting August 2, 2017 voted 12-1 against that safety data is adequate to support approval. 13-0 in favor of efficacy.
Guselkumab
Plaque psoriasis
Approved
Approved
Approval announced July 13, 2017.
SIMPONI ARIA
Ankylosing Spondylitis
Approved
Approved
Approval announced October 20, 2017.
SIMPONI ARIA
Psoriatic arthritis (PsA)
Approved
Approved
Approval announced October 20, 2017.
STELARA (USTEKINUMAB)
Plaque psoriasis
Approved
Approved
Approval announced October 13, 2017.
Imbruvica
Marginal zone lymphoma
Approved
Approved
sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
XARELTO (rivaroxaban)
Coronary Artery Disease or Peripheral Artery Disease
Phase 3
Phase 3
Phase 3 trial stopped early due to positive efficacy - February 8, 2017.
Imbruvica
Second-line Chronic graft-versus-host disease (GVHD)
Approved
Approved
Approval announced August 2, 2017.
Talacotuzumab
Acute myeloid leukemia (AML)
Phase 3
Phase 3
Phase 3 discontinuation announced October 17, 2017.

Latest News

  1. NEW BRUNSWICK, N.J., Jan. 4, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2021 of $1.01 per share on the company's common stock. The dividend is payable on March 9, 2021 to shareholders of record at the close of business on February 23, 2021. The ex-dividend date is February 22, 2021.

    About Johnson & Johnson
    At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach…

    NEW BRUNSWICK, N.J., Jan. 4, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2021 of $1.01 per share on the company's common stock. The dividend is payable on March 9, 2021 to shareholders of record at the close of business on February 23, 2021. The ex-dividend date is February 22, 2021.

    About Johnson & Johnson

    At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.                              

    (PRNewsfoto/Johnson & Johnson)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-announces-quarterly-dividend-for-first-quarter-2021-301200054.html

    SOURCE Johnson & Johnson

    View Full Article Hide Full Article
  2. NEW BRUNSWICK, N.J., Dec. 3, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today that Dr. Nadja West, retired United States Army lieutenant general and former United States Army Surgeon General has been appointed to its Board of Directors.

    "I am pleased to welcome Dr. Nadja West to Johnson & Johnson's Board of Directors," said Alex Gorsky, Chairman and Chief Executive Officer. "Nadja is an accomplished healthcare leader with a strong commitment to public service and she brings an impressive and unique combination of business and leadership expertise to Johnson & Johnson. I look forward to Nadja's contributions to the Board as we continue our pursuit of improving the health of families around the world at such an important moment…

    NEW BRUNSWICK, N.J., Dec. 3, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today that Dr. Nadja West, retired United States Army lieutenant general and former United States Army Surgeon General has been appointed to its Board of Directors.

    "I am pleased to welcome Dr. Nadja West to Johnson & Johnson's Board of Directors," said Alex Gorsky, Chairman and Chief Executive Officer. "Nadja is an accomplished healthcare leader with a strong commitment to public service and she brings an impressive and unique combination of business and leadership expertise to Johnson & Johnson. I look forward to Nadja's contributions to the Board as we continue our pursuit of improving the health of families around the world at such an important moment in time."

    About LTG(R) Dr. Nadja West

    Dr. Nadja West brings decades of strategic and operational experience in national and international executive leadership, strategic planning, and healthcare management. Most recently, Dr. West served as the 44th Army Surgeon General, and Commanding General of the US Army Medical Command from 2015-2019. Prior to that role, Dr. West served as the Joint Staff Surgeon from 2013-2015, Deputy Chief of Staff for Support, US Army Medical Command from 2012-2013, and Commanding General, Europe Regional Medical Command from 2010-2012. Dr. West currently serves as an Independent Director on the Boards of Nucor Corporation and Tenet Healthcare Corporation; serves as a Trustee of the National Recreation Foundation, and Mount St. Mary's University; and as a Board Member of Americares, and The Bob Woodruff Foundation.. Dr. West graduated from the United States Military Academy with a degree in General Engineering, The National War College with a master's degree in National Security and Strategic Studies and earned her M.D. at The George Washington University.

    "I am incredibly proud to join the Board of Directors at Johnson & Johnson," said Dr. Nadja West. "I look forward to working alongside the Board in support of the management team as they continue to deliver transformational innovation, create healthier communities, and put better health within reach of more people around the world."

    The full Board of Directors list is available on the Johnson & Johnson website at https://www.jnj.com/leadership/our-leadership-team#board-of-directors  

    About Johnson & Johnson

    At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

    (PRNewsfoto/Johnson & Johnson)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-names-dr-nadja-west-retired-united-states-army-lieutenant-general-and-former-united-states-army-surgeon-general-to-its-board-of-directors-301186123.html

    SOURCE Johnson & Johnson

    View Full Article Hide Full Article
  3. SANTA ANA, Calif., Dec. 1, 2020 /PRNewswire/ -- Today, Johnson & Johnson Vision* announced findings from a new survey** that assessed awareness of cataracts among adults around the world. Cataracts are the leading cause of blindness globally,1 with more than 90% of people developing cataracts by age 65.2 Yet, the survey reveals a significant lack of understanding of treatment options, including surgical procedures, to correct vision loss from cataracts.

    Around the world, the majority (70%) of people said they are familiar with cataracts and even more know that surgery is the most common treatment option (85%). However, among those diagnosed or who have symptoms of cataracts, only 30% of Americans surveyed said they would be very likely to undergo…

    SANTA ANA, Calif., Dec. 1, 2020 /PRNewswire/ -- Today, Johnson & Johnson Vision* announced findings from a new survey** that assessed awareness of cataracts among adults around the world. Cataracts are the leading cause of blindness globally,1 with more than 90% of people developing cataracts by age 65.2 Yet, the survey reveals a significant lack of understanding of treatment options, including surgical procedures, to correct vision loss from cataracts.

    Around the world, the majority (70%) of people said they are familiar with cataracts and even more know that surgery is the most common treatment option (85%). However, among those diagnosed or who have symptoms of cataracts, only 30% of Americans surveyed said they would be very likely to undergo cataract surgery. The most cited reason for not wanting to undergo cataract surgery was fear. Of those surveyed, 29% stated they are afraid of undergoing a cataract procedure and have concerns about the effectiveness of surgery (28%). In addition, many expressed a lack of knowledge about cataract procedures altogether (22%).

    "For many people suffering with cataracts, the word 'surgery' can be intimidating. However, cataract surgery is safe and effective. In fact, it's one of the most common outpatient procedures performed3," said Dr. Rajesh K. Rajpal, Chief Medical Officer and Global Head of Clinical and Medical Affairs, Johnson & Johnson Vision***. "This survey uncovered a critical need for increased education, dialogue and reassurance between patients, loved ones and eye care providers."

    Benefits of Treatment

    Donald Smith, age 70, is retired and volunteers at a history museum. He recently underwent cataract surgery and encourages everyone to act on their cataracts, meet with their doctor and discuss a plan that is right for them. Donald shared his experience and said, "My procedure went extremely well, and I have been opened to a whole new world of color and clarity. It was just like experiencing the Wizard of Oz movie, black and white to a vibrant world."

    Importance of Education

    According to Johnson & Johnson (NYSE:JNJ) research,4 3 out of 4 patients diagnosed with cataracts only discovered information about the condition and their treatment options post-diagnosis.

    "People need to know that cataracts are common and very effectively treated. The procedure is both safe and effective, with an extremely high success rate of improving patient vision. Additionally, cataract surgery techniques and technologies continue to evolve and advance, benefitting more patients than ever before. As eye care professionals, it is up to us to educate our patients on treatment options for cataracts, and that includes easing their fears by providing educational resources in channels where they're seeking out medical information - on social media and our practice websites," said Eric Donnenfeld, MD, Clinical Professor of Ophthalmology, New York University****.

    Johnson & Johnson Vision encourages everyone to Prioritize Your Eyes by educating yourself to make more informed decisions around your, or your loved ones, care and to understand options leading up to and following surgery. Through the Prioritize Your Eyes campaign, Johnson & Johnson Vision is providing resources to educate people about the benefits and safety of treating cataracts so patient can make more informed decisions. Additionally, more information and tools for patients and caregivers can be found at BeyondCataracts.com, including treatment information, an eye care professional locator and an interactive tool to help choose a lens that's best for each individual.

    About Cataracts

    More than 90% of people develop cataracts—the clouding and yellowing of the lens in the eye—by the age of 655. While part of the normal aging of the eye, left untreated, cataracts cause vision to deteriorate over time. In fact, cataracts are the leading cause of preventable blindness worldwide, impacting more than 100 million eyes6. Cataract surgery is one of the most common outpatient procedures performed today and has a success rate of approximately 98%7. Today, cataract treatments can also offer patients vision correction, reducing or eliminating the need for glasses, in addition to removing the cataract.8,9

    Risk Information

    While complications are rare, there are risks to routine cataract surgery.  This is irrelevant to the lens you choose. The problems could be minor, temporary, or affect your vision permanently. These may include worsening of your vision, bleeding, or infection. Pre-existing diseases or conditions (e.g., diabetes, heart disease, and previous eye trauma) may place you at higher risk of experiencing complications and/or more difficult recovery after routine cataract surgery. With some lenses, you may experience some loss in the sharpness of your vision, even with glasses. A small number of patients may want to have their IOL removed. This can be due to lens-related optical/visual symptoms. You should discuss all risks and benefits with your eye doctor before surgery.

    About Johnson & Johnson Vision*

    At Johnson & Johnson Vision, part of Johnson & Johnson Medical Devices Companies**, we have a bold ambition: to change the trajectory of eye health worldwide. Through our operating companies, we deliver innovation that enables eye care professionals to create better outcomes for patients throughout their lives, with products and technologies that address unmet needs including refractive error, cataracts, and dry eye. In communities with the greatest need, we work in collaboration to expand access to quality eye care, and we are committed to helping people see better, connect better, live better. Visit us at jjvision.com, follow @JNJVision on Twitter, Johnson & Johnson Vision on LinkedIn, and @JNJVision on Facebook.

    About Johnson & Johnson Medical Devices Companies*****

    At Johnson & Johnson Medical Devices Companies, we are helping people live their best lives. Building on more than a century of expertise, we tackle pressing healthcare challenges, and take bold steps that lead to new standards of care while improving people's healthcare experiences. In surgery, orthopaedics, vision, and interventional solutions, we are helping to save lives and paving the way to a healthier future for everyone, everywhere.

    *Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.

    **The survey was conducted online in August 2020 by TRUE Global Intelligence—the in-house research practice of FleishmanHillard—among more than 6,000 adults 18 years of age or older across the United States, Japan, China, Germany, Russia, and the United Kingdom.

    ***Dr. Rajesh K. Rajpal is an employee of Johnson & Johnson Surgical Vision, Inc., serving as Head of Clinical and Medical Affairs across both the Surgical Vision and Vision Care organizations.

    ****Dr. Eric Donnenfeld is a paid consultant of Johnson & Johnson Surgical Vision, Inc. and serves as Clinical Professor of Ophthalmology at New York University

    *****The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, vision, and interventional solutions businesses within Johnson & Johnson's Medical Devices segment. 

    © Johnson & Johnson Vision, 2020. All rights reserved.







    World Health Organization - Priority Eye Diseases. REF 2016 OTH 0004.

    2 University of Michigan Kellogg Eye Center website. http://www.kellogg.umich.edu/patientcare/conditions/cataract.html. Accessed October 28, 2017. REF 2016 OTH 0327.

    3 Vision Health Initiative, Common Eye Disorders. Centers for Disease Control and Prevention. https://www.cdc.gov/visionhealth/basics/ced/index.html

    Johnson & Johnson Vision internal presentation - Patient Media Habits Report. December 2019.

    5 Kellogg Eye Center. Cataract. https://www.umkelloggeye.org/conditions-treatments/cataract

    6 World Health Organization. Blindness and Impairment. https://www.who.int/en/news-room/fact-sheets/detail/blindness-and-visual-impairment 

    Vision Health Initiative, Common Eye Disorders. Centers for Disease Control and Prevention. https://www.cdc.gov/visionhealth/basics/ced/index.html

    8 All About Vision. Will I Need Glasses After Cataract Surgery? https://www.allaboutvision.com/conditions/faq-cataract-glasses-after-surgery.htm 

    9 Khandelwal SS, et. al. Effectiveness of multifocal and monofocal intraocular lenses for cataract surgery and lens replacement: a systematic review and meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2019 May;257(5):863-875. doi: 10.1007/s00417-018-04218-6.

     

     

    Cision View original content:http://www.prnewswire.com/news-releases/new-survey-finds-critical-need-for-education-on-cataracts-and-modern-treatment-options-301182072.html

    SOURCE Johnson & Johnson

    View Full Article Hide Full Article
  4. NEW BRUNSWICK, N.J., Nov. 17, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today $100 million in commitments and collaborations over the next five years to invest in and promote health equity solutions for Black people and other communities of color in the United States. Society has been significantly impacted by systemic racism, the COVID-19 pandemic, and the economic decline throughout this year, which have all spotlighted healthcare inequities.

    "There is an urgent need to take on the inequities rooted in systemic racism that threaten health in communities of color across the United States," said Alex Gorsky, Chairman and Chief Executive Officer of Johnson & Johnson. "That's why Johnson & Johnson is focusing its efforts and…

    NEW BRUNSWICK, N.J., Nov. 17, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today $100 million in commitments and collaborations over the next five years to invest in and promote health equity solutions for Black people and other communities of color in the United States. Society has been significantly impacted by systemic racism, the COVID-19 pandemic, and the economic decline throughout this year, which have all spotlighted healthcare inequities.

    "There is an urgent need to take on the inequities rooted in systemic racism that threaten health in communities of color across the United States," said Alex Gorsky, Chairman and Chief Executive Officer of Johnson & Johnson. "That's why Johnson & Johnson is focusing its efforts and committing $100 million to address racial and social injustice as the critical public health issue that it is. As the largest and most broadly-based healthcare company in the world, we are uniquely positioned to convene private, public and community organizations in pursuit of this shared aspiration—and work together to make a meaningful impact through science, business, public health, and philanthropy."

    The Company's commitment prioritizes three key areas: Healthier Communities – investing in programs that help provide equitable healthcare for underserved communities; Enduring Alliances – forging partnerships and alliances that combat racial and social health determinants; and Diverse & Inclusive Corporate Culture – ensuring a diverse and inclusive workforce.

    Healthier Communities

    "The quality of your healthcare should not be determined by your race and ethnicity," said Alex Gorsky. Johnson & Johnson is investing in culturally competent community care solutions that create healthier outcomes for Black people and other communities of color. Several key community programs are immediately underway, and others will be deployed.

    • In order to better connect clinical and medical care with social and cultural needs, Johnson & Johnson is introducing new scholarships, mentoring and non-financial support to improve representation of people of color in medical, scientific, and health professions.
    • The Company will strengthen community health by providing technology enhancements and mobile health solutions, that put health within reach of underserved and minority populations through partnerships with Community Based Clinics and Federally Qualified Health Centers.
    • Johnson & Johnson is undertaking a major initiative to increase access and participation in clinical trials in diverse populations.
    • While health equity efforts will go beyond the COVID-19 pandemic, knowing communities of color have been disproportionally impacted, the Company has funded mobile vans to extend the reach of care in high-need and hard-to-reach areas to support COVID-19 testing, starting with Detroit and New Orleans. Further, the Company is seeking diverse enrollment in the COVID-19 vaccine clinical trials to inform the safety and effectiveness of the vaccine.
    • As a kick-start effort to bring health equity ideas forward directly from those impacted, Johnson & Johnson will partner with local community leaders, businesses and entrepreneurs in six major cities across America to identify and invest in scalable and sustainable healthcare solutions that have the potential to create a positive impact for communities of color.

    Enduring Alliances

    "Our 130+ year history in healthcare, science and technology gives us access to a global network that we will activate and inspire to join us in influencing systemic change that positively impacts the quality of healthcare for Black people and other communities of color," said Michael Sneed, Executive Vice President, Global Corporate Affairs & Chief Communications Officer, Johnson & Johnson.

    Johnson & Johnson is leveraging its global network to also address social, environmental, and economic determinants related to health inequities. The Company is partnering with universities, health systems, NGOs and governments to build breakthrough coalitions to develop and expand economic, education and social programs that close the health disparity divide.

    • Starting in 2021, the Company will introduce alliances, collaborations and partnerships that support health equity solutions and educational programming ranging from maternal health resources to inspiring black students to pursue science and health careers.
    • Johnson & Johnson is partnering with The Executive Leadership Council to provide college scholarships and other resources to Black students who have a passion for STEM, business, or healthcare-related fields.
    • The Company will invest in partnerships that address the disproportionate health impact of climate change on communities of color.

    In addition to its commitment to health equity, through the Johnson & Johnson Supply Chain, the Company is also proud to commit several hundred million in annual spend with Black and Hispanic owned businesses over the next five years to drive positive social and economic impact.

    Diverse & Inclusive Corporate Culture

    "Our long-standing commitment to diversity, equity, and inclusion gives us the foundation to drive sustainable change. We are accelerating and expanding our efforts to strengthen our inclusive culture and build a workforce that reflects the diversity of the patients and communities we serve." said Wanda Hope, Chief Diversity & Inclusion Officer, Johnson & Johnson.

    Internally, Johnson & Johnson remains focused on cultivating a diverse and inclusive workforce that inspires innovative healthcare solutions around the world.

    • The Company is committed to hiring more diverse employees and has set a goal of achieving 50% growth of its African American talent at the manager and above levels in the U.S. over the next five years.
    • Johnson & Johnson is also enhancing HR processes to optimize how it accesses, hires, and develops talent, and is offering cultural immersion programs to enhance awareness and understanding.

    Johnson & Johnson will make multi-million-dollar investments in Healthier Communities and Enduring Alliances programs, while the investment made in its Diverse & Inclusive Corporate Culture will largely focus on enhancing processes, training, and education. Although this announcement represents immediate action, Johnson & Johnson's commitment to address racial and social injustice is enduring.

    ABOUT JOHNSON & JOHNSON

    At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

    Note to Investors Concerning Forward-Looking Statements

    This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of The Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global healthcare reforms; trends toward healthcare cost containment; changes in behavior and spending patterns of purchasers of healthcare products and services; financial instability of international economies and legal systems and sovereign risk; and increased scrutiny of the healthcare industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in The Company's most recently filed Quarterly Report on Form 10-Q, and The Company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.govwww.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

    (PRNewsfoto/Johnson & Johnson)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-to-address-racial-and-social-injustice-through-platform-that-aims-to-eliminate-health-inequities-for-people-of-color-301174429.html

    SOURCE Johnson & Johnson

    View Full Article Hide Full Article
  5. NEW BRUNSWICK, N.J., Nov. 14, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) (the Company) announced the expansion to the partnership between its Janssen Pharmaceutical Companies (Janssen) and the Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services for the ongoing development of Janssen's investigational COVID-19 vaccine candidate.

    Under the amendment, Janssen will commit approximately $604 million and BARDA will commit approximately $454 million to support the ongoing Phase 3 ENSEMBLE trial evaluating Janssen's investigational COVID-19 vaccine candidate as a single-dose in up to 60,000…

    NEW BRUNSWICK, N.J., Nov. 14, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) (the Company) announced the expansion to the partnership between its Janssen Pharmaceutical Companies (Janssen) and the Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services for the ongoing development of Janssen's investigational COVID-19 vaccine candidate.

    Under the amendment, Janssen will commit approximately $604 million and BARDA will commit approximately $454 million to support the ongoing Phase 3 ENSEMBLE trial evaluating Janssen's investigational COVID-19 vaccine candidate as a single-dose in up to 60,000 volunteers worldwide.

    Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson, said, "We greatly value the ongoing confidence and support of our investigational COVID-19 vaccine candidate development program. Combined with our own significant investment, this agreement has enabled our vital research and development and underscores the importance of public-private partnerships to tackle the worldwide COVID-19 pandemic."

    This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under OTA No. HHSO100201700018C.

    Johnson & Johnson affirmed its commitment to develop and test its Janssen COVID-19 vaccine candidate in accordance with high ethical standards and sound scientific principles, as outlined in a pledge made by nine vaccine manufacturers earlier this year.

    For more information on Johnson & Johnson's multi-pronged approach to combatting the pandemic, visit: www.jnj.com/coronavirus.

    About Johnson & Johnson

    At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Learn more at www.jnj.com. Follow us at @JNJNews.

    About the Janssen Pharmaceutical Companies

    At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at www.janssen.com. Follow us at @JanssenGlobal.

    Notice to Investors Concerning Forward-Looking Statements

    This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding development of a potential preventive vaccine for COVID-19. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies, and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

    (PRNewsfoto/Johnson & Johnson)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-and-us-department-of-health--human-services-expand-agreement-to-support-next-phase-of-covid-19-vaccine-candidate-research-and-development-301173112.html

    SOURCE Johnson & Johnson

    View Full Article Hide Full Article
View All Johnson & Johnson News